Industry

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Contract Manufacturing & Research Services Market Research Report by Service (Manufacturing and Research), End-user, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Pharmaceutical Contract Manufacturing & Research Services Market size was estimated … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Alzheimer’s Disease Therapeutics and Diagnostics Market 2022-2028” report has been added to ResearchAndMarkets.com’s offering. MARKET OUTLOOK The publisher estimates the global Alzheimer’s disease therapeutics and diagnostics market to grow with a CAGR of 6.98% in the years 2022-2028. The high prevalence of Alzheimer’s disease (AD) and the growing elderly populace are key … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Single-cell Analysis Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global single-cell analysis market. This report focuses on single-cell analysis market which is experiencing strong growth. The report gives a guide to the … [Read more…]

STRASBOURG, France–(BUSINESS WIRE)–Braintale, a medtech deciphering white matter, spin off from the Paris Greater Hospitals has been awarded by the scientific committee of the 34th Eastern NeuroRadiology Society (ENRS), whose annual meeting was held in Burlington (Virginia, United States) on August 19th – 21st, 2022, the Robert D. Zimmerman Scientific Award for its communication. Entitled … [Read more…]

ALACHUA, Fla.–(BUSINESS WIRE)–Lacerta Therapeutics, a leader in the development of adeno-associated virus (AAV) technologies for the treatment of central nervous system (CNS) diseases, today announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The collaboration will focus on the discovery and development … [Read more…]

Product line expanded to include NuCLEANase, an enzyme that has a wide range of potential applications in the food industry The course for future growth has been set: c-LEcta has secured over 10,000 m² of building space for its new headquarters at Alte Messe Leipzig LEIPZIG, Germany–(BUSINESS WIRE)–c-LEcta, a global biotechnology company with technology leadership … [Read more…]

AWANS, Belgium–(BUSINESS WIRE)–#MVO–Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) technology. The PiCSO-AMI-II multicenter, randomized trial will enroll 300 patients with anterior ST-segment Elevation Myocardial Infarction (STEMI) presenting with … [Read more…]

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone TOKYO & MUNICH–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and … [Read more…]

Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon’s core diluted EPS in 2024 Ad … [Read more…]

Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon’s core diluted EPS in 2024 Ad … [Read more…]